METFORALTAG Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

metforaltag

laboratori guidotti s.p.a. - metformina - metformina

YALTORMIN Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

yaltormin

pinewood laboratories limited - metformina - metformina

IDROCLOROTIAZIDE AUROBINDO Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

idroclorotiazide aurobindo

aurobindo pharma (italia) s.r.l. - idroclorotiazide - idroclorotiazide

SITAGLIPTIN E METFORMINA GALENICUM Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

sitagliptin e metformina galenicum

galenicum health, s.l. - metformina e sitagliptina - metformina e sitagliptina

Artesunate Amivas Unione Europea - italiano - EMA (European Medicines Agency)

artesunate amivas

amivas ireland ltd - artesunate - malaria - antiprotozoari - artesunate amivas is indicated for the initial treatment of severe malaria in adults and children. dovrebbero essere prese in considerazione le linee guida ufficiali sull'uso appropriato degli agenti antimalarici.

Sitagliptin / Metformin hydrochloride Mylan Unione Europea - italiano - EMA (European Medicines Agency)

sitagliptin / metformin hydrochloride mylan

mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - diabete mellito, tipo 2 - farmaci usati nel diabete - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. , triplice terapia di associazione) in aggiunta alla dieta e all'esercizio fisico in pazienti non adeguatamente controllati il loro dosaggio massimo tollerato di metformina ed una sulfonilurea. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.